Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Journal of Cancer Survivorship : Research and Practice|April 28, 2024
Determining the relationship of p16INK4a and additional molecular markers of aging with clinical frailty in hematologic malignancyAshley E Rosko, Mohamed I Elsaid, Jennifer Woyach, et al.
Frontiers in Oncology|January 31, 2022
Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMAJustin Watts, Tara L Lin, Alice Mims, et al.
Leukemia & Lymphoma|March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
British Journal of Haematology|December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasmStéphane De Botton, Christian Récher, Jorge Cortes, et al.
Molecular and Cellular Biology|April 30, 2014
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signalingBo Cen, Ying Xiong, Jin H Song, et al.
Cancers|January 10, 2026
Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation TrialShivani Handa, Kristin Koenig, Qiuhong Zhao, et al.
Leukemia & Lymphoma|June 12, 2024
Impact of chronic graft-versus-host disease on non-relapse mortality and survivalJustin Jiang, Audrey M Sigmund, Qiuhong Zhao, et al.
Leukemia & Lymphoma|November 24, 2020
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDSBrendan Rasor, Tyler Dickerson, Qiuhong Zhao, et al.
Journal of Geriatric Oncology|November 6, 2024
Predictive ability of the Cancer and Aging Research Group chemotherapy toxicity calculator in hematologic malignancyAshley E Rosko, Ying Huang, Sarah A Wall, et al.
Blood Advances|August 30, 2023
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemiaFarhad Ravandi, Asad Bashey, James Foran, et al.
Pageof 5